Clinical Trials Logo

Advanced Urothelial Carcinoma clinical trials

View clinical trials related to Advanced Urothelial Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06196736 Not yet recruiting - Clinical trials for Advanced Urothelial Carcinoma

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Start date: December 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.

NCT ID: NCT06079112 Not yet recruiting - Clinical trials for Advanced Urothelial Carcinoma

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Start date: October 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.

NCT ID: NCT05687721 Not yet recruiting - Clinical trials for Advanced Urothelial Carcinoma

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with metastatic bladder cancer are usually treated with chemotherapy. If their cancers do not progress after chemotherapy, they can be enrolled into this study and receive a standard-of-care immunotherapy medication named avelumab plus a study drug named copanlisib.

NCT ID: NCT04064190 Not yet recruiting - Clinical trials for Advanced Urothelial Carcinoma

Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Start date: October 15, 2021
Phase: Phase 2
Study type: Interventional

This is Phase 2, open label, non randomized single arm study to determine whether the administration of vactosertib with durvalumab will provide meaningful increases in the Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a response with anti-PD-1/PD-L1 based regimens